Jasper Therapeutics (JSPR) Total Liabilities (2019 - 2026)

Jasper Therapeutics has reported Total Liabilities for 8 years, with the latest figure at $10.4 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 54.76% year-over-year to $10.4 million in Q2 2026; TTM through Jun 2026 was $10.4 million, a 54.76% decrease from a year earlier, with the FY2025 full-year figure at $31.6 million, up 73.54% from the prior year.
• Total Liabilities was $10.4 million for Q2 2026 at Jasper Therapeutics, down from $31.6 million in the prior quarter.
• The five-year high for Total Liabilities was $45.9 million in Q3 2025, with the low at $10.4 million in Q2 2026.
• Average Total Liabilities over 5 years is $17.3 million, with a median of $14.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities sank 59.65% in 2022, then surged 191.73% in 2025.
• Over 5 years, Total Liabilities stood at $12.4 million in 2022, then soared by 32.98% to $16.5 million in 2023, then advanced by 10.78% to $18.2 million in 2024, then soared by 73.54% to $31.6 million in 2025, then sank by 67.15% to $10.4 million in 2026.
• The last three Total Liabilities figures came in at $10.4 million (Q2 2026), $31.6 million (Q4 2025), and $45.9 million (Q3 2025), per Business Quant data.